Understanding Dolutegravir for HIV Treatment | Clinical Benefits & Efficacy
Dolutegravir is an integrase strand transfer inhibitor (INSTI) used in the treatment of HIV-1 infection. It works by blocking the integrase enzyme, which HIV uses to insert its genetic material into human cells.
Dolutegravir 50mg (brand name TAPIVIR 50) from Taj Pharma is a WHO-GMP certified formulation used as part of combination antiretroviral therapy (ART) for HIV treatment.
Used as part of combination therapy for HIV-1 infected adults and adolescents.
Recommended as first-line antiretroviral therapy by WHO and major health organizations.
Effective for treatment-experienced patients with HIV-1 infection.
Helps suppress viral load and improve CD4 count in HIV patients.
Dolutegravir works by inhibiting the integrase enzyme of HIV-1. This enzyme is responsible for integrating the viral DNA into the host cell's chromosome. By blocking this process, dolutegravir prevents HIV from replicating and spreading to new cells.
Clinical trials have demonstrated that dolutegravir-based regimens achieve viral suppression (HIV RNA <50 copies/mL) in over 90% of treatment-naive patients and significant proportions of treatment-experienced patients.
| Patient Population | Efficacy Rate |
|---|---|
| Treatment-Naive Adults | >90% viral suppression |
| Treatment-Experienced | 80-90% viral suppression |
| Integrase Inhibitor-Naive | >95% viral suppression |
Rapid viral load reduction within weeks of starting therapy.
Generally well tolerated with minimal adverse effects.
Once-daily dosing improves treatment adherence.
Long-term viral suppression with sustained CD4 recovery.
Explore more about our products and services
Browse our complete range of Dolutegravir tablets and pharmaceutical products.
View AllRequest a competitive quote for your bulk orders with flexible payment terms.
Request QuoteRead articles about HIV treatment, Dolutegravir, and pharmaceutical industry updates.
Read Blog